Institute for Digestive Health and Liver Disease
Research facility
Location:
Baltimore, MD,
United States (USA) (US)
ISNI: -
Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018)
Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al.
Conference contribution